Literature DB >> 23077239

Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen.

Bree Foley1, Sarah Cooley, Michael R Verneris, Julie Curtsinger, Xianghua Luo, Edmund K Waller, Claudio Anasetti, Daniel Weisdorf, Jeffrey S Miller.   

Abstract

We have previously shown that NKG2C(+) NK cells from CMV naive umbilical cord blood grafts expand preferentially in recipients after CMV reactivation, representing a primary NK cell response after hematopoietic cell transplantation. In this study, recipients of adult donor hematopoietic cell transplantation were assessed to evaluate the role of donor/recipient CMV serostatus on the expression and function of NKG2C(+) NK cells to determine responses to secondary CMV events. Expansion of NKG2C(+) NK cells was seen following clinical CMV reactivation. However, they also expanded in the absence of detectable CMV viremia when both the donor and recipient were CMV seropositive. Upregulation of NKG2C was observed in NK cells from CMV-positive recipients receiving grafts from CMV-seropositive or -seronegative donors. These in vivo-expanded NKG2C(+) NK cells had an increased capacity for target cell-induced cytokine production, expressed an inhibitory killer Ig-like receptor for self-HLA and preferentially acquired CD57. Most importantly, NKG2C(+) NK cells transplanted from seropositive donors exhibit heightened function in response to a secondary CMV event compared with NKG2C(+) NK cells from seronegative donors. We conclude that NKG2C(+) memory-like NK cells are transplantable and require active or latent (subclinical) expression of CMV Ag in the recipient for clonal expansion of NK cells previously exposed to CMV in the donor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23077239      PMCID: PMC3490031          DOI: 10.4049/jimmunol.1201964

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

Review 1.  New aspects of natural-killer-cell surveillance and therapy of cancer.

Authors:  Mark J Smyth; Yoshihiro Hayakawa; Kazuyoshi Takeda; Hideo Yagita
Journal:  Nat Rev Cancer       Date:  2002-11       Impact factor: 60.716

2.  Licensing of natural killer cells by host major histocompatibility complex class I molecules.

Authors:  Sungjin Kim; Jennifer Poursine-Laurent; Steven M Truscott; Lonnie Lybarger; Yun-Jeong Song; Liping Yang; Anthony R French; John B Sunwoo; Suzanne Lemieux; Ted H Hansen; Wayne M Yokoyama
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

3.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

Review 4.  The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Authors:  Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

5.  Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40.

Authors:  P Tomasec; V M Braud; C Rickards; M B Powell; B P McSharry; S Gadola; V Cerundolo; L K Borysiewicz; A J McMichael; G W Wilkinson
Journal:  Science       Date:  2000-02-11       Impact factor: 47.728

Review 6.  Activation, coactivation, and costimulation of resting human natural killer cells.

Authors:  Yenan T Bryceson; Michael E March; Hans-Gustaf Ljunggren; Eric O Long
Journal:  Immunol Rev       Date:  2006-12       Impact factor: 12.988

7.  Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts.

Authors:  Mónica Gumá; Matthias Budt; Andrea Sáez; Tamara Brckalo; Hartmut Hengel; Ana Angulo; Miguel López-Botet
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

8.  Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.

Authors:  Peter Hillmen; Aleksander B Skotnicki; Tadeusz Robak; Branimir Jaksic; Anna Dmoszynska; Jingyang Wu; Cynthia Sirard; Jiri Mayer
Journal:  J Clin Oncol       Date:  2007-11-05       Impact factor: 44.544

9.  Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

Authors:  Jeanette Lundin; Eva Kimby; Magnus Björkholm; Per-Anders Broliden; Fredrik Celsing; Viktoria Hjalmar; Lars Möllgård; Peppy Rebello; Geoff Hale; Herman Waldmann; Håkan Mellstedt; Anders Osterborg
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

10.  Imprint of human cytomegalovirus infection on the NK cell receptor repertoire.

Authors:  Mónica Gumá; Ana Angulo; Carlos Vilches; Natalia Gómez-Lozano; Núria Malats; Miguel López-Botet
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

View more
  167 in total

Review 1.  Natural killer cell memory in infection, inflammation and cancer.

Authors:  Adelheid Cerwenka; Lewis L Lanier
Journal:  Nat Rev Immunol       Date:  2016-01-25       Impact factor: 53.106

2.  Activating Receptors for Self-MHC Class I Enhance Effector Functions and Memory Differentiation of NK Cells during Mouse Cytomegalovirus Infection.

Authors:  Tsukasa Nabekura; Lewis L Lanier
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

3.  Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing αβ+T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies.

Authors:  Letizia Muccio; Alice Bertaina; Michela Falco; Daniela Pende; Raffaella Meazza; Miguel Lopez-Botet; Lorenzo Moretta; Franco Locatelli; Alessandro Moretta; Mariella Della Chiesa
Journal:  Haematologica       Date:  2015-12-11       Impact factor: 9.941

Review 4.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Authors:  Richard W Childs; Mattias Carlsten
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

5.  Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall.

Authors:  M Noviello; A Forcina; V Veronica; R Crocchiolo; M T L Stanghellini; M Carrabba; R Greco; L Vago; F Giglio; A Assanelli; M R Carbone; Z Magnani; F Crippa; C Corti; M Bernardi; J Peccatori; C Bordignon; F Ciceri; C Bonini; A Bondanza
Journal:  Bone Marrow Transplant       Date:  2015-06-15       Impact factor: 5.483

6.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Authors:  E Liu; Y Tong; G Dotti; H Shaim; B Savoldo; M Mukherjee; J Orange; X Wan; X Lu; A Reynolds; M Gagea; P Banerjee; R Cai; M H Bdaiwi; R Basar; M Muftuoglu; L Li; D Marin; W Wierda; M Keating; R Champlin; E Shpall; K Rezvani
Journal:  Leukemia       Date:  2017-07-20       Impact factor: 11.528

Review 7.  Memory responses of natural killer cells.

Authors:  Clair D Geary; Joseph C Sun
Journal:  Semin Immunol       Date:  2017-08-30       Impact factor: 11.130

8.  NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs.

Authors:  Vivien Béziat; Lisa L Liu; Jenny-Ann Malmberg; Martin A Ivarsson; Ebba Sohlberg; Andreas T Björklund; Christelle Retière; Eva Sverremark-Ekström; James Traherne; Per Ljungman; Marie Schaffer; David A Price; John Trowsdale; Jakob Michaëlsson; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

9.  Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.

Authors:  Jeffrey S Miller; Cliona M Rooney; Julie Curtsinger; Ron McElmurry; Valarie McCullar; Michael R Verneris; Natalia Lapteva; David McKenna; John E Wagner; Bruce R Blazar; Jakub Tolar
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-09       Impact factor: 5.742

10.  Murine NK cell intrinsic cytokine-induced memory-like responses are maintained following homeostatic proliferation.

Authors:  Molly P Keppel; Liping Yang; Megan A Cooper
Journal:  J Immunol       Date:  2013-03-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.